Welcome to our dedicated page for Novartis SEC filings (Ticker: NVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novartis AG (NVS) SEC filings page on Stock Titan provides access to the company’s US regulatory disclosures, including Form 20‑F annual reports and Form 6‑K current reports. As a foreign private issuer based in Basel, Switzerland, Novartis uses these filings to communicate with US investors about financial performance, capital markets activity, clinical and regulatory milestones, and strategic transactions.
Form 6‑K reports frequently incorporate press releases on key events such as US Food and Drug Administration (FDA) approvals, major trial readouts and business development deals. Recent 6‑K filings have included announcements of FDA approvals for Rhapsido (remibrutinib) in chronic spontaneous urticaria, Vanrafia (atrasentan) for reduction of proteinuria in primary IgA nephropathy, Fabhalta (iptacopan) for C3 glomerulopathy, Leqvio (inclisiran) label expansion for hypercholesterolemia, and Itvisma (onasemnogene abeparvovec‑brve) for spinal muscular atrophy in older children, teens and adults. Other 6‑K filings detail positive Phase III results for ianalumab in Sjögren’s disease, multi‑asset collaborations, and the planned acquisition of Avidity Biosciences.
Investors can also find financial information in Novartis filings, such as quarterly financial reports, constant‑currency sales guidance and core operating margin disclosures. Certain 6‑K filings cover debt offerings by Novartis Capital Corporation, including terms agreements and forms of guaranteed debt securities for various note maturities, which are incorporated into the company’s shelf registration statements.
Stock Titan enhances these filings with AI‑powered summaries that explain the significance of each document in clear language. Users can quickly understand how a new 6‑K about a clinical trial result, an FDA decision, or a strategic acquisition may relate to Novartis’s pipeline and growth outlook. The filings page updates as new documents are posted to EDGAR, helping users follow NVS regulatory communications in near real time. While insider transaction details for Novartis are reported under applicable rules, this page focuses on the company’s primary SEC submissions, including 20‑F annual reports, 6‑K current reports, and related exhibits.
NVS: Form 144 filing reporting proposed sale of American Depositary Shares. The filer reports 6,800 American Depositary Shares to be sold tied to restricted stock vesting on 01/29/2026. The filing also records 7,500 ADS sold during the past three months on 02/09/2026 with an associated figure of $1,171,575.75.
Novartis reported softer Q1 2026 earnings despite solid growth from key drugs. Net sales were USD 13.1 billion, down 1% reported and 5% at constant currency, as strong volume growth was more than offset by US generic competition and lower pricing.
Operating income fell 9% to USD 4.2 billion and net income declined 13% to USD 3.2 billion, with EPS at USD 1.65. Core EPS was USD 1.99, down 13%. Free cash flow remained resilient at USD 3.3 billion, broadly in line with last year.
Growth was driven by priority brands including Kisqali (+55% cc to USD 1.5 billion), Pluvicto, Kesimpta, Scemblix and Leqvio, while Entresto, Promacta and Tasigna declined sharply from generics. Novartis completed the roughly USD 12 billion Avidity Biosciences acquisition, lifting net debt to USD 38.1 billion, but reaffirmed 2026 guidance for low single-digit net sales growth and a low single-digit decline in core operating income at constant currency.
Novartis AG filed a Form 6-K to incorporate documents related to a large multi-tranche U.S. dollar notes issuance by Novartis Capital Corporation into its existing Form F-3 shelf registration.
The filing covers a $500,000,000 Floating Rate Notes issue due 2029 and six series of fixed-rate notes: $1,250,000,000 of 4.100% Notes due 2029, $1,750,000,000 of 4.400% Notes due 2031, $2,000,000,000 of 4.600% Notes due 2033, $2,250,000,000 of 4.900% Notes due 2036, $1,000,000,000 of 5.600% Notes due 2046, and $2,250,000,000 of 5.700% Notes due 2056.
The exhibits include the terms agreement with a syndicate of underwriters, forms of guaranteed debt securities for each series, an officer’s certificate, and legal opinions and consents from U.S. and Swiss counsel.
Novartis AG is offering an aggregate of $11,000,000,000 in notes, fully and unconditionally guaranteed by Novartis AG.
The offering comprises seven series: $500,000,000 floating rate notes due March 16, 2029 (Compounded SOFR + 0.650%) and six fixed-rate series totaling $10,500,000,000 with coupons from 4.100% to 5.700% and maturities from 2029 through 2056. Net proceeds of approximately $10,910.7 million are intended for general corporate purposes, including repayment of the Avidity Bridge Loan.
Novartis Capital Corporation proposes an offering of multiple series of senior notes, including floating rate notes tied to Compounded SOFR and several fixed rate notes maturing between 2029 and 2056, each fully and unconditionally guaranteed by Novartis AG. The offering contemplates book-entry issuance in minimum denominations of $2,000 and includes optional redemption provisions, tax‑related redemption rights, and benchmark transition mechanics for the SOFR‑linked notes. The net proceeds are intended for general corporate purposes outside Switzerland, including repayment of the Avidity Bridge Loan financing the Avidity Biosciences acquisition.
The prospectus supplement discloses that Novartis AG reported $54.5 billion in net sales and $14.0 billion net income from continuing operations for 2025, and that Novartis Capital Corporation is a wholly owned indirect subsidiary of Novartis AG established to issue debt and provide proceeds to affiliates.
A holder of the issuer’s American Depositary Shares has filed a notice of planned resale under Rule 144. The filing covers 30,743 American Depositary Shares, with an aggregate market value of 4,960,276.69, to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/12/2026. These shares were acquired on 01/29/2026 via restricted stock vesting as compensation from the issuer. The filing notes that shares of the same class outstanding total 1,908,151,679.
An affiliate of the issuer has filed a notice of proposed sale covering 7500 American Depositary Shares, to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/09/2026 and an aggregate market value of 1171575.75.
The securities relate to a larger base of 1908151679 shares outstanding. The 7500 shares were acquired on 01/29/2026 via restricted stock vesting from the issuer as compensation, and this notice confirms the holder’s representation that they are not aware of undisclosed material adverse information about the issuer.
Novartis furnished a report on Form 6-K that provides investors with access to its latest annual information. The filing submits the Novartis Annual Report 2025 and the Report on Nonfinancial Matters 2025 as exhibits, making these documents officially available under U.S. securities law for foreign private issuers.
Novartis reported solid 2025 results with higher sales, profits and cash generation. Full‑year net sales reached USD 54.5 billion, up 8% at constant currencies, driven by strong volume growth partly offset by generic competition and pricing pressure.
Profitability improved meaningfully. Operating income rose to USD 17.6 billion (up 21%), while core operating income increased to USD 21.9 billion, lifting the core margin to 40.1% of net sales. Free cash flow was USD 17.6 billion, up 8%.
Key growth brands such as Kisqali, Kesimpta, Pluvicto, Cosentyx and Scemblix delivered strong double‑digit growth, and the pipeline advanced with new approvals and positive Phase III results in oncology, immunology and rare diseases. The Board proposes a dividend of CHF 3.70 per share, a 5.7% increase, and continued large share repurchases reduced shares outstanding by 66.9 million, contributing to a 22% rise in EPS to USD 7.21.